The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
What You Should Know: – Emergency doctors in the UK have said many electronic health records (EHRs) in use are close to being unacceptable, and this is likely to be having a negative impact on patient care. A national survey of more than 1500 members… Read More »UK ED Dept. Shows Poor Usability for Major EHRs, Survey Finds
What You Should Know: – DTx and Patient Support leaders, Amalgam Rx, Inc., announce the acquisition of Avhana Health, a privately-held clinical decision support (CDS) company. Amalgam Rx, Inc., a Wilmington, DE-based Digital Therapeutics and Patient Support company, announces the acquisition of Avhana Health, a… Read More »Amalgam Rx Acquires Clinical Decision Support Platform Avhana Health – M&A
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.